Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.
With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results